Pulse Biosciences (PLSE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
11 May, 2026Executive summary
The annual meeting will be held virtually on June 11, 2026, with voting on director elections and auditor ratification.
Seven directors are nominated for election to serve until the 2027 annual meeting.
Deloitte & Touche LLP is proposed for ratification as the independent auditor for fiscal year 2026.
Stockholders of record as of April 28, 2026, are eligible to vote, with multiple voting methods available.
The Board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposal 1: Election of seven directors by plurality vote.
Proposal 2: Ratification of Deloitte & Touche LLP as independent auditor for 2026, requiring majority approval.
Shareholders may submit proposals for the 2027 meeting by January 11, 2027, following specific bylaw procedures.
No cumulative voting is permitted; each share equals one vote.
Board of directors and corporate governance
The Board separates the roles of CEO and Co-Chairmen for effective oversight.
Five of seven directors are independent under Nasdaq rules.
Committees include Audit, Compensation, Nominating and Corporate Governance, and Strategic Advisory.
Directors are evaluated on ethics, experience, independence, and diversity.
A code of business conduct and an amended insider trading policy are in place.
Latest events from Pulse Biosciences
- nsPFA technology delivers breakthrough efficacy in AFib and is poised for broad clinical adoption.PLSE
Canaccord Genuity's 46th Annual Growth Conference - nsPFA delivers superior ablation outcomes with robust IP and strong clinical and financial momentum.PLSE
Investor presentation - Pivotal trial enrollment accelerated, cash rose to $101.6M, and net loss reached $24.7M.PLSE
Q2 2026 - Directors and auditor ratified as company advances AFib trial and strengthens leadership.PLSE
AGM 2026 - Nanosecond PFA platform shows superior efficacy and is on track for early 2028 launch.PLSE
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Nanosecond PFA shows strong clinical promise in AFib, with accelerated pivotal study progress.PLSE
Bank of America Global Healthcare Conference 2026 - nsPFA platform drives clinical and market expansion with strong evidence and robust IP protection.PLSE
Corporate presentation - Accelerated pivotal trial progress, strong data, and $18.6M net loss with $0.4M revenue.PLSE
Q1 2026 - Advanced pivotal clinical programs in AF ablation with rising losses and modest initial revenue.PLSE
Q4 2025